EffRx Supports the 16th Annual Rare Disease Day on 28. February 2023

Our Products

The product portfolio is led by already commercialized Binosto® for the treatment of postmenopausal osteoporosis.

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States

Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced …

World Orphan Drug Alliance (WODA) Marks their First Anniversary

To read more click title

Abiogen Pharma Completes the Acquisition of EffRx

EffRx Pharmaceuticals SA joins forces with Abiogen Pharma S.p.A. Read PR: Abiogen & EffRx Press Release

Scroll to Top